Abstract

The modern-day clinical laboratory has evolved in response to clinical demands and a need to adopt a steady stream of new technologies. Among the technological innovations that have had a large impact are computing and informatics, automation, antibody-based analytical methods, nucleic acid sequencing and probing techniques, sensor technology, and luminescence-based sensing techniques, such as chemiluminescence and fluorescence. The changing landscape of healthcare provides a continuing stimulus to the evolution of clinical testing, both in central laboratories and at the point of care. Progress in miniaturization has created devices with micrometer-sized features designed to perform a range of assays and that integrate all of the steps in an assay onto a single small device—the so-called lab-on-a-chip. The next step in miniaturization is the descent from the micrometer scale to the nanometer scale and the exploitation of nanotechnology—nanosized structures in the interval from 1 to 100 nm. Nanotechnology is now a major area of research and development. Many applications for nanosized materials (e.g., nanoparticles) have emerged in in vitro diagnostics, imaging, and therapeutics. In common with many types of new development, the arrival of nanotechnology has been heralded by considerable hype about its potential and future promise, but these high expectations have been tempered by concerns over the technology's safety (1). This new technological area is multifaceted and already has found extensive applications in >1000 consumer products (http://sis.nlm.nih.gov/enviro/nanotechnology.html; http://www.nanotechproject.org/inventories/consumer/). In clinical testing, 2 avenues of exploitation that have emerged are the use of nanoscale materials as reagents (e.g., nanoparticle labels and therapeutic agents) (2, 3) and the development of nanoscale devices (e.g., nanopores) (4). The latter is a distant prospect, and most work has centered on the former application. In this Q&A, Dawn Bonnell, Amit Kulkarni, Joseph Wang, Yuri Miyahara, and David Ure, experts in the field of nanotechnology, answer …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.